Advanced search
Publication Cover
Expert Review of Molecular Diagnostics Volume 12, 2012 - Issue 6
Submit an article Journal homepage
306
Views
128
CrossRef citations to date
0
Altmetric
Review

How many molecular subtypes? Implications of the unique tumor principle in personalized medicine

Shuji Ogino Department of Pathology, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA, USA. [email protected]; Department of Medical Oncology, and Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA; Cancer Epidemiology Program, Dana-Farber/Harvard Cancer Center, Boston, MA, USA; Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA; Department of Pathology, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA, USA. [email protected]; Department of Medical Oncology, and Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA; Cancer Epidemiology Program, Dana-Farber/Harvard Cancer Center, Boston, MA, USA; Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
,
Charles S Fuchs Department of Medical Oncology, and Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA; Cancer Epidemiology Program, Dana-Farber/Harvard Cancer Center, Boston, MA, USA; Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA; Department of Medical Oncology, and Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA; Cancer Epidemiology Program, Dana-Farber/Harvard Cancer Center, Boston, MA, USA; Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
&
Edward Giovannucci Cancer Epidemiology Program, Dana-Farber/Harvard Cancer Center, Boston, MA, USA; Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA; Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA; Department of Nutrition, Harvard School of Public Health, Boston, MA, USA; Cancer Epidemiology Program, Dana-Farber/Harvard Cancer Center, Boston, MA, USA; Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA; Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA; Department of Nutrition, Harvard School of Public Health, Boston, MA, USA
Pages 621-628 | Published online: 09 Jan 2014

References

  • Baudhuin LM, Donato LJ, Uphoff TS. How novel molecular diagnostic technologies and biomarkers are revolutionizing genetic testing and patient care. Expert Rev. Mol. Diagn.12(1), 25–37 (2012).
  • Roukos DH. Novel clinico–genome network modeling for revolutionizing genotype–phenotype-based personalized cancer care. Expert Rev. Mol. Diagn.10(1), 33–48 (2010).
  • Metodiev MV. Biomarkers research in Europe: focus on personalized medicine. Expert Rev. Mol. Diagn.11(7), 689–690 (2011).
  • Hamilton SR. Targeted therapy of cancer: new roles for pathologists in colorectal cancer. Mod. Pathol.21(Suppl. 2), S23–S30 (2008).
  • Gulley ML, Braziel RM, Halling KC et al. Clinical laboratory reports in molecular pathology. Arch. Pathol. Lab. Med.131(6), 852–863 (2007).
  • Tonellato PJ, Crawford JM, Boguski MS, Saffitz JE. A national agenda for the future of pathology in personalized medicine: report of the proceedings of a meeting at the Banbury Conference Center on genome-era pathology, precision diagnostics, and preemptive care: a stakeholder summit. Am. J. Clin. Pathol.135(5), 668–672 (2011).
  • Funkhouser WK, Lubin IM, Monzon FA et al. Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the Association for Molecular Pathology. J. Mol. Diagn.14(2), 91–103 (2012).
  • Febbo PG, Ladanyi M, Aldape KD et al. NCCN Task Force report: evaluating the clinical utility of tumor markers in oncology. J. Natl Comp. Canc. Netw.9(Suppl. 5), S1–S32; quiz S33 (2011).
  • Baylin SB, Jones PA. A decade of exploring the cancer epigenome – biological and translational implications. Nat. Rev. Cancer11(10), 726–734 (2011).
  • Van Engeland M, Derks S, Smits KM, Meijer GA, Herman JG. Colorectal cancer epigenetics: complex simplicity. J. Clin. Oncol.29(10), 1382–1391 (2011).
  • Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat. Rev. Gastroenterol. Hepatol.8(12), 686–700 (2011).
  • Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut60(1), 116–129 (2011).
  • Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J. Natl Cancer Inst.102(6), 365–367 (2010).
  • Ogino S, Galon J, Fuchs CS, Dranoff G. Cancer immunology-analysis of host and tumor factors for personalized medicine. Nat. Rev. Clin. Oncol.8(12), 711–719 (2011).
  • Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut60(3), 397–411 (2011).
  • Begg CB. A strategy for distinguishing optimal cancer subtypes. Int. J. Cancer129(4), 931–937 (2011).
  • Ogino S, King EE, Beck AH, Sherman ME, Milner DA, Giovannucci E. Interdisciplinary education to integrate pathology and epidemiology: towards molecular and population-level health science. Am. J. Epidemiol. (2012) (In press).
  • Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell61(5), 759–767 (1990).
  • Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J. Mol. Diagn.10(1), 13–27 (2008).
  • Hansen KD, Timp W, Bravo HC et al. Increased methylation variation in epigenetic domains across cancer types. Nat. Genet.43(8), 768–775 (2011).
  • Siegmund KD, Marjoram P, Tavare S, Shibata D. High DNA methylation pattern intratumoral diversity implies weak selection in many human colorectal cancers. PLoS ONE6(6), e21657 (2011).
  • Berger AH, Knudson AG, Pandolfi PP. A continuum model for tumour suppression. Nature476(7359), 163–169 (2011).
  • Allen M, Louise Jones J. Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J. Pathol.223(2), 162–176 (2011).
  • Soto AM, Sonnenschein C. The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory. Bioessays33(5), 332–340 (2011).
  • Lee HO, Silva AS, Concilio S et al. Evolution of tumor invasiveness: the adaptive tumor microenvironment landscape model. Cancer Res.71(20), 6327–6337 (2011).
  • Xia D, Wang D, Kim SH, Katoh H, Dubois RN. Prostaglandin E(2) promotes intestinal tumor growth via DNA methylation. Nat. Med.18(2), 224–226 (2012).
  • O’Hagan HM, Wang W, Sen S et al. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG islands. Cancer Cell20(5), 606–619 (2011).
  • Wood LD, Parsons DW, Jones S et al. The genomic landscapes of human breast and colorectal cancers. Science318(5853), 1108–1113 (2007).
  • Chapman MA, Lawrence MS, Keats JJ et al. Initial genome sequencing and analysis of multiple myeloma. Nature471(7339), 467–472 (2011).
  • The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature474(7353), 609–615 (2011).
  • Ding L, Getz G, Wheeler DA et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature455(7216), 1069–1075 (2008).
  • Sjoblom T, Jones S, Wood LD et al. The consensus coding sequences of human breast and colorectal cancers. Science314(5797), 268–274 (2006).
  • Jones S, Zhang X, Parsons DW et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science321(5897), 1801–1806 (2008).
  • Jiao Y, Shi C, Edil BH et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science331(6021), 1199–1203 (2011).
  • Parsons DW, Jones S, Zhang X et al. An integrated genomic analysis of human glioblastoma multiforme. Science321(5897), 1807–1812 (2008).
  • Varela I, Tarpey P, Raine K et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature469(7331), 539–542 (2011).
  • Morin RD, Mendez-Lago M, Mungall AJ et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature476(7360), 298–303 (2011).
  • Parsons DW, Li M, Zhang X et al. The genetic landscape of the childhood cancer medulloblastoma. Science331(6016), 435–439 (2011).
  • Berger MF, Lawrence MS, Demichelis F et al. The genomic complexity of primary human prostate cancer. Nature470(7333), 214–220 (2011).
  • Jones S, Wang TL, Shih IEM et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science330(6001), 228–231 (2010).
  • Coppede F. Epigenetic biomarkers of colorectal cancer: focus on DNA methylation. Cancer Lett. doi:10.1016/j.canlet.2011.12.030 (2012) (Epub ahead of print).
  • Curtin K, Slattery ML, Samowitz WS. CpG island methylation in colorectal cancer: past, present and future. Patholog. Res. Int.2011, 902674 (2011).
  • Hughes LA, Khalid-De Bakker CA, Smits KM et al. The CpG island methylator phenotype in colorectal cancer: progress and problems. Biochim. Biophys. Acta1825(1), 77–85 (2012).
  • Berman HK, Gauthier ML, Tlsty TD. Premalignant breast neoplasia: a paradigm of interlesional and intralesional molecular heterogeneity and its biological and clinical ramifications. Cancer Prev. Res. (Phila.)3(5), 579–587 (2010).
  • Michor F, Polyak K. The origins and implications of intratumor heterogeneity. Cancer Prev. Res. (Phila.)3(11), 1361–1364 (2010).
  • Dornan D, Settleman J. Dissecting cancer heterogeneity. Nat. Biotechnol.29(12), 1095–1096 (2011).
  • Marusyk A, Almendro V, Polyak K. Intratumor heterogeneity: a looking glass for cancer. Nat. Rev. Cancer12(5), 323–334 (2012).
  • Dalerba P, Kalisky T, Sahoo D et al. Single-cell dissection of transcriptional heterogeneity in human colon tumors. Nat. Biotechnol.29(12), 1120–1127 (2011).
  • Navin N, Kendall J, Troge J et al. Tumour evolution inferred by single-cell sequencing. Nature472(7341), 90–94 (2011).
  • Merlo LM, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat. Rev. Cancer6(12), 924–935 (2006).
  • Loeb LA. Human cancers express mutator phenotypes: origin, consequences and targeting. Nat. Rev. Cancer11(6), 450–457 (2011).
  • Amos-Landgraf JM, Irving AA, Hartman C et al. Monoallelic silencing and haploinsufficiency in early murine intestinal neoplasms. Proc. Natl Acad. Sci. USA109(6), 2060–2065 (2012).
  • Al-Mulla F, Milner-White EJ, Going JJ, Birnie GD. Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression. J. Pathol.187(4), 433–438 (1999).
  • De Roock W, Jonker DJ, Di Nicolantonio F et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA304(16), 1812–1820 (2010).
  • Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl Acad. Sci. USA105(7), 2652–2657 (2008).
  • Liao X, Morikawa T, Lochhead P et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin. Cancer Res.18(8), 2257–2268 (2012).
  • Monzon FA, Ogino S, Hammond EH, Halling KC, Bloom KJ, Nikiforova MN. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch. Pathol. Lab. Med.133(10), 1600–1606 (2009).
  • Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology138(6), 2073–2087.e3 (2010).
  • Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N. Engl. J. Med.361(25), 2449–2460 (2009).
  • Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA96(15), 8681–8686 (1999).
  • Samowitz W, Albertsen H, Herrick J et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology129(3), 837–845 (2005).
  • Nosho K, Irahara N, Shima K et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS ONE3(11), e3698 (2008).
  • Hinoue T, Weisenberger DJ, Lange CP et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res.22(2), 271–282 (2012).
  • Estecio MR, Gharibyan V, Shen L et al. LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS ONE2(5), e399 (2007).
  • Ogino S, Kawasaki T, Nosho K et al. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG methylator phenotype in colorectal cancer. Int. J. Cancer122, 2767–2773 (2008).
  • Ibrahim AE, Arends MJ, Silva AL et al. Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression. Gut60(4), 499–508 (2011).
  • Sunami E, De Maat M, Vu A, Turner RR, Hoon DS. LINE-1 hypomethylation during primary colon cancer progression. PLoS ONE6(4), e18884 (2011).
  • Baba Y, Huttenhower C, Nosho K et al. Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. Mol. Cancer9, 125 (2010).
  • Suehiro Y, Wong CW, Chirieac LR et al. Epigenetic–genetic interactions in the APC/WNT, RAS/RAF, and p53 pathways in colorectal carcinoma. Clin. Cancer Res.14(9), 2560–2569 (2008).
  • Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J. Mol. Diagn.8, 582–588 (2006).
  • Shen L, Toyota M, Kondo Y et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc. Natl Acad. Sci. USA104(47), 18654–18659 (2007).
  • Ogino S, Kawasaki T, Kirkner GJ, Suemoto Y, Meyerhardt JA, Fuchs CS. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Gut56, 1409–1416 (2007).
  • Dahlin AM, Palmqvist R, Henriksson ML et al. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin. Cancer Res.16(6), 1845–1855 (2010).
  • Ogino S, Nosho K, Kirkner GJ et al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J. Natl Cancer Inst.100, 1734–1738 (2008).
  • Ahn JB, Chung WB, Maeda O et al. DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer117(9), 1847–1854 (2011).
  • Hughes LA, Williamson EJ, Van Engeland M et al. Body size and risk for colorectal cancers showing BRAF mutation or microsatellite instability: a pooled analysis. Int. J. Epidemiol. doi:10.1093/ije/dys055 (2012) (Epub ahead of print).
  • Ogino S, Giovannucci E. Lifestyle factors and colorectal cancer microsatellite instability: molecular pathological epidemiology science, based on unique tumor principle (commentary). Int. J. Epidemiol. doi:10.1093/ije/dys076 (2012) (Epub ahead of print).
  • Kuller LH. The twenty-first century epidemiologist: need for different training? Am. J. Epidemiol. (2012) (In Press).
  • Ogino S, Beck AH, King EE, Sherman ME, Milner DA, Giovannucci E. Need for molecular pathological epidemiology (MPE) and MPEist in 21st century: keeping up with next generation science. Am. J. Epidemiol. (2012) (In Press).
  • Hughes LA, Simons CC, Van Den Brandt PA et al. Body size, physical activity and risk of colorectal cancer with or without the CpG island methylator phenotype (CIMP). PLoS ONE6(4), e18571 (2011).
  • Boyle T, Fritschi L, Heyworth J, Bull F. Long-term sedentary work and the risk of subsite-specific colorectal cancer. Am. J. Epidemiol.173(10), 1183–1191 (2011).
  • Kelley RK, Wang G, Venook AP. Biomarker use in colorectal cancer therapy. J. Natl Comp. Canc. Netw.9(11), 1293–1302 (2011).
  • Chen D, Song S, Lu J et al. Functional variants of -1318T>G and -673C>T in c-Jun promoter region associated with increased colorectal cancer risk by elevating promoter activity. Carcinogenesis32(7), 1043–1049 (2011).
  • Campbell PT, Newton CC, Dehal AN, Jacobs EJ, Patel AV, Gapstur SM. Impact of body mass index on survival after colorectal cancer diagnosis: The Cancer Prevention Study-II Nutrition Cohort. J. Clin. Oncol.30(1), 42–52 (2012).
  • Boyle T, Heyworth J, Bull F, Mckerracher S, Platell C, Fritschi L. Timing and intensity of recreational physical activity and the risk of subsite-specific colorectal cancer. Cancer Causes Control22(12), 1647–1658 (2011).
  • Gehoff A, Basten O, Sprenger T et al. Optimal lymph node harvest in rectal cancer (UICC stages II and III) after preoperative 5-FU-based radiochemotherapy. Acetone compression is a new and highly efficient method. Am. J. Surg. Pathol.36(2), 202–213 (2012).
  • Iwagami S, Baba Y, Watanabe M et al. Pyrosequencing assay to measure LINE-1 methylation level in esophageal squamous cell carcinoma. Ann. Surg. Oncol. doi:10.1245/s10434–011–2176–3 (2011) (Epub ahead of print).
  • Esteban S, Moya P, Fernandez-Suarez A, Vidaurreta M, Gonzalez-Peramato P, Sanchez-Carbayo M. Diagnostic and prognostic utility of methylation and protein expression patterns of myopodin in colon cancer. Tumour Biol.33(2), 337–346 (2012).
  • Limburg PJ, Limsui D, Vierkant RA et al. postmenopausal hormone therapy and colorectal cancer risk in relation to somatic KRAS mutation status among older women. Cancer Epidemiol. Biomarkers Prev.21(4), 681–684 (2012).
  • Swedlow JR, Lewis SE, Goldberg IG. Modelling data across labs, genomes, space and time. Nat. Cell Biol.8(11), 1190–1194 (2006).
  • Ghosh S, Matsuoka Y, Asai Y, Hsin KY, Kitano H. Software for systems biology: from tools to integrated platforms. Nat. Rev. Genet.12(12), 821–832 (2011).
  • Papp B, Notebaart RA, Pal C. Systems-biology approaches for predicting genomic evolution. Nat. Rev. Genet.12(9), 591–602 (2011).
  • Loscalzo J, Barabasi AL. Systems biology and the future of medicine. Wiley Interdiscip. Rev. Syst. Biol. Med.3(6), 619–627 (2011).
  • Paez JG, Janne PA, Lee JC et al.EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science304(5676), 1497–1500 (2004).
  • Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med.350(21), 2129–2139 (2004).
  • Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med.363(18), 1693–1703 (2010).
  • Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol.26(10), 1626–1634 (2008).
  • Karapetis CS, Khambata-Ford S, Jonker DJ et al.K-RAS mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med.359(17), 1757–1765 (2008).
  • Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med.360(14), 1408–1417 (2009).
  • Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med.363(9), 809–819 (2010).
  • Bollag G, Hirth P, Tsai J et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature467(7315), 596–599 (2010).
  • Straussman R, Morikawa T, Shee K et al. Tumor microenvironment contributes to innate RAF-inhibitor resistance through HGF secretion. Nature (2012) (In Press).
  • Heinrich MC, Owzar K, Corless CL et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J. Clin. Oncol.26(33), 5360–5367 (2008).
  • Demetri GD, Benjamin RS, Blanke CD et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST) – update of the NCCN clinical practice guidelines. J. Natl Comp. Canc. Netw.5(Suppl. 2), S1–S29; quiz S30 (2007).
  • Prahallad A, Sun C, Huang S et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature483(7387), 100–103 (2012).
  • Fox EJ, Loeb LA. Lethal mutagenesis: targeting the mutator phenotype in cancer. Semin. Cancer Biol.20(5), 353–359 (2010).
  • Martini M, Vecchione L, Siena S, Tejpar S, Bardelli A. Targeted therapies: how personal should we go? Nat. Rev. Clin. Oncol.9(2), 87–97 (2011).
  • La Thangue NB, Kerr DJ. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat. Rev. Clin. Oncol.8(10), 587–596 (2011).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.